Aps

Two new compounds developed at the Vanderbilt University Warren Center for Neuroscience Drug Discovery will enable research into a protein family with ties to Alzheimer’s disease, setting the stage for the development of a different kind of therapeutic than is currently available. Read More

A new potential treatment for schizophrenia discovered through the Warren Center for Neuroscience Drug Discovery at Vanderbilt University has entered phase 1 clinical trials, marking the fifth WCNDD therapeutic to advance into human testing. Read More

Bingshan Li and his lab are changing the paradigm of how geneticists can identify risk genes for schizophrenia, enabling new studies into its underlying biology and opening new doors for the development of treatments against it. Read More

Researchers from the Warren Center for Neuroscience Drug Discovery, in collaboration with Boehringer Ingelheim, developed a compound that can treat both negative and positive symptoms of schizophrenia in rodents. The compound holds promise as an investigational tool and an inspiration for novel schizophrenia therapies. Read More

Led by Craig W. Lindsley, Vanderbilt drug discovery experts set out to develop a backup drug candidate to improve memory loss in people with Alzheimer’s disease. Read More

By Natalya Ortolano Confocal laser scanning microscopy image of the dorsal cord of a young adult showing a VD motor neuron with spine-like protrusions, and a close-up of the spines. Figure reproduced and modified under a CC BY 4.0 license from eLife 2019;8:e47918. When Nobel laureate Santiago… Read More